Basilea Pharmaceutica Stock Price, News & Analysis (OTCMKTS:BPMUF) $41.00 0.00 (0.00%) (As of 12/7/2023 ET) Add Compare Share Share Today's Range$41.00▼$41.0050-Day Range$41.00▼$50.0052-Week Range$41.00▼$41.00VolumeN/AAverage VolumeN/AMarket Capitalization$485.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest About Basilea Pharmaceutica Stock (OTCMKTS:BPMUF)Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing, a small-molecule inhibitor of DXR, as well as in phase ½ clinical trial for urothelial and gastric cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.Read More BPMUF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPMUF Stock News HeadlinesDecember 4, 2023 | finance.yahoo.comBasilea Pharmaceutica AG's (VTX:BSLN) top owners are individual investors with 58% stake, while 39% is held by institutionsNovember 20, 2023 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this yearDecember 8, 2023 | Edge On The Street (Ad)An Unusual Way to Invest in GoldMost financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines. November 13, 2023 | msn.comPfizer unit in pact with Swiss biotech Basilea to sell rights to antifungalNovember 13, 2023 | finance.yahoo.comBasilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungalOctober 31, 2023 | finance.yahoo.comBasilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agentOctober 19, 2023 | finance.yahoo.comBasilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infectionsOctober 17, 2023 | finance.yahoo.comBasilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023December 8, 2023 | Edge On The Street (Ad)Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.October 2, 2023 | finance.yahoo.comBasilea announces FDA acceptance of New Drug Application for antibiotic ceftobiproleSeptember 28, 2023 | finance.yahoo.comBasilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremiaAugust 15, 2023 | finance.yahoo.comBasilea reports strong revenue and profit growth in first half-year 2023August 4, 2023 | markets.businessinsider.comBasilea Pharma Submits NDA For Antibiotic CeftobiproleAugust 4, 2023 | finance.yahoo.comBasilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiproleJune 8, 2023 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to BasileaApril 18, 2023 | finance.yahoo.comBasilea provides update on New Drug Application to the US Food and Drug Administration for antibiotic ceftobiproleFebruary 14, 2023 | markets.businessinsider.comBasilea Pharmaceutica Posts FY ProfitFebruary 14, 2023 | finance.yahoo.comBasilea reports strong financial results 2022 based on successful implementation of new strategyFebruary 7, 2023 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers second sales milestone payment to Basilea from PfizerJanuary 24, 2023 | markets.businessinsider.comBasilea Pharma Expects Net Profit In FY22January 24, 2023 | finance.yahoo.comBasilea reports preliminary operating profit for 2022, significantly above guidanceJanuary 11, 2023 | finance.yahoo.comBasilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio updateJanuary 9, 2023 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 20 million sales milestone payment to BasileaDecember 28, 2022 | finance.yahoo.comBasilea announces repayment of 2022 convertible bondsDecember 23, 2022 | finance.yahoo.comBasilea announces regulatory approval of antifungal Cresemba® (isavuconazole) in JapanDecember 19, 2022 | finance.yahoo.comBasilea announces transition milestone for oncology asset BAL0891, triggering milestone payment of USD 4 million by SillaJenDecember 14, 2022 | finance.yahoo.comHere's Why Momentum in Basilea Pharmaceutica AG (BPMUF) Should Keep goingSee More Headlines Receive BPMUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BPMUF CUSIPN/A CIKN/A Webwww.basilea.com Phone(161) 606-1111Fax41-61-606-1112Employees143Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio7.55 Current Ratio2.77 Quick Ratio2.38 Sales & Book Value Annual Sales$154.86 million Price / Sales3.14 Cash Flow$1.17 per share Price / Cash Flow35.01 Book Value($1.83) per share Price / Book-22.40Miscellaneous Outstanding Shares11,851,000Free FloatN/AMarket Cap$485.89 million OptionableNot Optionable Beta0.82 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. David Veitch (Age 58)Chief Executive Officer Comp: $1.35MMr. Adesh Kaul (Age 49)Chief Financial Officer Dr. Gerrit Hauck Ph.D. (Age 59)Chief Technology Officer Dr. Laurenz Kellenberger Ph.D. (Age 56)Chief Scientific Officer Dr. Marc Engelhardt M.D. (Age 59)Chief Medical Officer Dr. Peer Nils SchroderHead of Corporate Communications & Investor RelationsMr. Damian Heller (Age 57)General Counsel & Corporate Secretary Ms. Ursula Eberhardt (Age 61)Head of Global Human Resources Mr. Mark Jones (Age 55)Head of Project Management & Preclinical Development Mr. Peter Bielmeier Ph.D. (Age 56)Head of Global Quality Management More ExecutivesKey CompetitorsORIC PharmaceuticalsNASDAQ:ORICLyell ImmunopharmaNASDAQ:LYELARS PharmaceuticalsNASDAQ:SPRY23andMeNASDAQ:MEEnliven TherapeuticsNASDAQ:ELVNView All Competitors BPMUF Stock Analysis - Frequently Asked Questions How have BPMUF shares performed in 2023? Basilea Pharmaceutica's stock was trading at $52.00 at the beginning of the year. Since then, BPMUF stock has decreased by 21.2% and is now trading at $41.00. View the best growth stocks for 2023 here. Are investors shorting Basilea Pharmaceutica? Basilea Pharmaceutica saw a decrease in short interest during the month of October. As of October 31st, there was short interest totaling 258,800 shares, a decrease of 9.0% from the October 15th total of 284,400 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 2,588.0 days. View Basilea Pharmaceutica's Short Interest. How do I buy shares of Basilea Pharmaceutica? Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does Basilea Pharmaceutica have any subsidiaries? The following companies are subsidiares of Basilea Pharmaceutica: Conec UK Limited.Read More This page (OTCMKTS:BPMUF) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Basilea Pharmaceutica AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.